Sep 10, 2026 08:05AM
Sep 8, 2026 08:00AM
Aug 27, 2026 08:00AM
Aug 27, 2026 08:00AM
Aug 6, 2026 04:05PM
Aug 6, 2026 04:01PM
Aug 6, 2026 04:01PM Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital 
Jul 30, 2026 08:00AM
Jul 21, 2026 08:00AM
Jul 21, 2026 08:00AM
Jun 22, 2026 08:05AM
Jun 22, 2026 08:05AM
May 28, 2026 08:05AM
May 13, 2026 08:00AM Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 12, 2026 04:01PM
May 5, 2026 04:06PM
May 5, 2026 04:05PM
May 5, 2026 08:00AM
Apr 9, 2026 04:05PM
Apr 6, 2026 08:00AM
Mar 11, 2026 08:00AM Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 5, 2026 08:00AM
Feb 23, 2026 08:00AM
Feb 12, 2026 08:00AM
Feb 12, 2026 08:00AM
Feb 9, 2026 08:03AM
Feb 9, 2026 08:00AM
Jan 7, 2026 11:34AM TD Cowen on Verrica Pharmaceuticals (VRCA): 'We are encouraged by the increased Ycanth prescribing in lieu of compounded cantharidin'
Jan 7, 2026 08:00AM
Jan 7, 2026 08:00AM
Nov 24, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 14, 2025 04:05PM
Nov 10, 2025 08:00AM
Nov 10, 2025 08:00AM Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
Nov 5, 2025 06:36AM
Oct 20, 2025 04:06PM
Oct 20, 2025 04:05PM
Oct 7, 2025 04:05PM
Oct 7, 2025 04:05PM
Sep 19, 2025 08:02AM
Sep 19, 2025 08:00AM Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Sep 2, 2025 07:00AM
Aug 12, 2025 04:01PM
Aug 12, 2025 04:01PM
Aug 6, 2025 07:00AM
Jul 9, 2025 07:02AM
Jul 9, 2025 07:00AM
Jul 1, 2025 07:00AM Verrica Pharmaceuticals (VRCA) Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment
Jul 1, 2025 07:00AM

330,677 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All